Neurology Central

RNA as a stroke biomarker

A biomarker to aid in the diagnosis of ischemic stroke and its causes would be of value in acute clinical practice. It could have applications to aid in acute stroke treatment decisions for tissue plasminogen activator and/or the triage to endovascular therapy. A stroke biomarker may also be useful to identify stroke etiology and guide stroke prevention treatments. This review provides an overview of RNA as a novel biomarker for the diagnosis and assessment of ischemic stroke. Topics addressed include RNA to identify acute ischemic stroke; RNA to identify transient ischemic attack; RNA to predict large vessel, cardioembolic and small vessel cause of stroke; and RNA to predict risk of tissue plasminogen activator related hemorrhagic transformation. Emerging methods to measure RNA as a point-of-care assay include microfluidics sorting and electrochemical sensors.

Stroke is a leading cause of disability and mortality worldwide [1,2]. Enhanced delivery of acute stroke treatments and stroke prevention therapy would improve stroke outcomes and reduce the burden on healthcare resources. Biomarkers have the potential to improve stroke care. They may have applications in the diagnosis of stroke, particularly in acute settings where the rapid triage of stroke patients to centers with stroke expertise is critical to improve outcomes. A biomarker may aid in the diagnosis of stroke etiology, and thus guide stroke prevention therapy. Biomarkers may also have applications for stratifying risk of stroke and complications, and predicting response to stroke treatment. In this review, we summarize and discuss RNA as a biomarker for stroke.

Read the full article here.